|
1 |
Decreased use of glucocorticoids in biological-experienced patients with rheumatoid arthritis who initiated intravenous abatacept: results from the 2-year ACTION study
Alten, Rieke. - Erlangen : Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 2016
|
|
|
|
2 |
Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study
Nüßlein, Hubert G.. - London : BioMed Central, 2016
|
|
|
|
3 |
Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study
Erlangen : Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 2015
|
|
|
|
4 |
High Levels of SOX5 Decrease Proliferative Capacity of Human B Cells, but Permit Plasmablast Differentiation
Erlangen : Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 2014
|
|
|
|
5 |
Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study
Erlangen : Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 2014
|
|
|
6 |
Obesity and risk of respiratory tract infections: results of an infection-diary based cohort study
Enthalten in BMC public health Bd. 18, 20.2.2018, Nr. 1, date:12.2018: 1-13
|
|
|
|
7 |
Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study
Enthalten in BMC musculoskeletal disorders Bd. 16, 30.7.2015, Nr. 1, date:12.2015: 1-11
|
|
|
|
8 |
Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study
Enthalten in BMC musculoskeletal disorders Bd. 15, 11.1.2014, Nr. 1, date:12.2014: 1-13
|
|
Administration
